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Recapitulating how genetic modification technology and its agro-food products aroused strong societal oppo-
sition in the European Union, this paper demonstrates how this opposition contributed to shape the European
regulatory frame on GM crops. More specifically, it describes how this opposition contributed to a de facto mora-
torium on the commercialization of new GM crop events in the end of the nineties. From this period onwards,
the regulatory frame has been continuously revised in order to slow down further erosion of public and market
confidence. Various scientific and technical reforms were made to meet societal concerns relating to the safety
of GM crops. In this context, the precautionary principle, environmental post-market monitoring and traceability
were adopted as ways to cope with scientific uncertainties. Labeling, traceability, co-existence and public infor-
mation were installed in an attempt to meet the general public request for more information about GM agro-food
products, and the specific demand to respect the consumers’ and farmers’ freedom of choice. Despite these ef-
forts, today, the explicit role of public participation and/or ethical consultation during authorization procedures
is at best minimal. Moreover, no legal room was created to progress to an integral sustainability evaluation
during market procedures. It remains to be seen whether the recent policy shift towards greater transparency
about value judgments, plural viewpoints and scientific uncertainties will be one step forward in integrating
ethical concerns more explicitly in risk analysis. As such, the regulatory frame stands open for further inter-
pretation, reflecting in various degrees a continued interplay with societal concerns relating to GM agro-food
products. In this regard, both societal concerns and diversely interpreted regulatory criteria can be inferred as
signaling a request – and even a quest – to render more explicit the broader-than-scientific dimension of the
actual risk analysis.
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INTRODUCTION
Compared to any other recent agricultural advance, ge-
netically modified (GM) agro-food products induced a
broad and intensive societal opposition in the European
Union (EU). Even nowadays, the latest Eurobarometer
survey shows that “GM food is widely seen as not being
useful, as morally unacceptable and as a risk for society”
(Gaskell et al., 2006). This opposition signals a request –
and even a quest – to render more explicit the broader-
than-scientific dimension of the actual risk analysis of
GM agro-food products. Scientifically trained experts and
lay people are known to perceive risks diﬀerently (Marris
et al., 2001; Slovic, 1987; Wynne, 2001). Experts tend
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to describe risks in objective and factual terms, whilst
lay people widely complement the concept of risk with
concerns about usefulness, socio-economic impacts, free-
dom of choice, unnaturalness of genetic modification, re-
spect for nature, long-term and irreversible consequences,
democracy, disparities between the industrialized world
and the third world, scientific uncertainties, fallibility of
experts, uncontrollability and/or sustainability of agricul-
ture (Cook et al., 2004; Deckers, 2005; Frewer et al.,
2004; Lassen and Jamison, 2006; Lassen et al., 2002;
Madsen and Sandøe, 2005; Shaw, 2002; Townsend, 2006;
Verhoog et al., 2003). In the EU, this diﬀerence in risk
perception contributed to a public distrust towards sci-
entists, policy makers and regulatory procedures (Frewer
et al., 2004; Marris et al., 2001; Siegrist, 2000). To slow
down further growth of this distrust, various researchers
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recommended (1) to make scientific opinions more trans-
parent by denoting explicitly the factual and normative
premises on which they are based; (2) to allow the contri-
bution of diverse publics in the processes of risk analysis
by organizing participatory exercises; and/or (3) to imple-
ment an integral sustainability evaluation that integrates
societal concerns by, for instance, weighing of possible
risks and benefits, comparing technological alternatives,
testing the usefulness or assessing the whole agricul-
tural system (ACRE, 2006; COGEM, 2003; Deblonde
and du Jardin, 2005; Frewer et al., 2004; Genus and
Coles, 2005; Irwin, 2006; Jensen and Sandøe, 2002;
Krayer von Krauss et al., 2004; Mayer and Stirling, 2002;
Nielsen and Faber, 2002; Nowotny, 2003; Schot, 2001;
Wandall, 2004). In practice, as a response to the societal
opposition towards GM agro-food products, a de facto
moratorium on the commercialization of new GM crop
events was put in place in the EU from 1999 to 2004. Dur-
ing this moratorium the regulatory frame on GM crops
was thoroughly revised in order to improve public and
market confidence. Specific values, norms, criteria and
principles already present in the regulatory frame were
strengthened, whilst new ones were implemented.
Exploring these events in detail via a historical recon-
struction, this paper illustrates how GM crops destined
for food, feed, cultivation, import, industrial processing
and/or experimental purposes aroused considerable so-
cietal opposition in the EU. We will discuss how this
opposition contributed to shape the European regulatory
frame on GM agro-food products. Hence, the European
GM crop legislation would have taken another path in the
absence of societal contestation. We will discuss whether
and which societal concerns were implemented explicitly
or implicitly, how their expression and meaning evolved,
and how some of these legal criteria are translated in prac-
tice. Finally, we will consider to what extent the estab-
lished regulatory frame, which became one of the most
stringent regimes in the world, will be helpful in pacify-
ing the conflict in the EU and which concerns currently
fall out of the regulatory scope.
RISK ANALYSIS OF GM CROPS
In the EU, the use of GM crops for food, feed, culti-
vation, import, industrial processing and/or experimen-
tal purposes is subjected to a risk analysis prior to
use. Risk analysis is a process consisting of three inter-
related components: risk assessment, risk management
and risk communication. In risk assessment, potential
adverse impacts associated with a specific activity are
scientifically characterized. In risk management, pol-
icy alternatives to accept, minimize or reduce the char-
acterized risks are weighed and, if needed, appropri-
ate prevention and control options are selected. Risk
communication is generally defined as an interactive ex-
change of information and opinions on risk throughout
risk analysis, running between risk assessors, risk man-
agers and other interested parties. It includes the ex-
planation of risk assessment findings and of the basis
on which risk management decisions are made (EFSA,
2004b; Johnson et al., 2007).
In theory, there is a functional and temporal sepa-
ration between risk assessment and risk management in
order to reduce any conflict of interest and to protect
the scientific integrity of risk assessment (de Sadeleer,
2006). Most societal concerns arising from the use of GM
crops fall beyond the scope of risk assessment (which
comes first in the process of risk analysis). They are at
best debated elsewhere in specifically established ad hoc
committees with appropriate expertise or in participatory
initiatives usually organized by Technology Assessment
bodies (Carr and Levidow, 2000; Genus and Coles, 2005;
Irwin, 2006; Nielsen and Faber, 2002; Schot, 2001). As a
result, most societal concerns generally are at play only
in risk management, after a risk assessment has been
done. In this view, risk assessment is depicted as a sound,
science-based and objective approach to assess the safety
of genetically modified organisms (GMOs), which leaves
no space for values (Johnson et al., 2007).
However, in practice, values appear to be inherent to
risk assessment, since there is a permanent interplay be-
tween risk assessment and risk management (de Sadeleer,
2006; Jensen and Sandøe, 2002; Levidow et al., 2005;
Nielsen and Faber, 2002; Wandall, 2004; Wynne, 2001).
This implicitly integrates an ethical perspective to the sci-
entific view on risk assessment. Value judgments are re-
quired to characterize risks and to determine the accept-
ability of health and environmental impacts. Judgments
are made about which kinds of harm to assess or ignore
and about what baseline of comparison to use for assess-
ing the severity and acceptability of risks (Carr, 2002).
In the words of Jensen et al. (2003), “risk assessment
views the world through a risk window that only makes
visible what has been predefined as a relevant risk, and
the size and structure of this window is determined by
value judgments as to what is considered to be an adverse
eﬀect within what is considered the relevant horizon of
time and space”. It means that scientific data and proce-
dures used in risk assessment fit into an evolving norma-
tive frame of values, norms, criteria and principles, par-
tially set by legislation. In this way, the regulatory frame
– that is the product of processes in democratic political
systems – functions as a moral guide in risk assessment.
Values also enter into risk assessment through a number
of scientific methodological choices that are made to de-
scribe the world and map its consequences (Jensen and
Sandøe, 2002; Murphy et al., 2006; Nielsen and Faber,
2002; Wandall, 2004).
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FIRST WAVE OF EUROPEAN LEGISLATIONS
ON GM CROPS
Because the techniques used for genetic modification
were new and raised specific safety concerns, a process-
based regulatory supervision of GMOs was deemed
necessary in the EU (Guehlstorf and Hallstrom, 2005;
Murphy et al., 2006). Similar safety concerns led to a res-
olution of the European Parliament in the eighties, call-
ing for a ban on the deliberate release of GMOs, as long
as binding legislations covering these releases were not
in place in Europe. In the summer of 1987, the Euro-
pean Community legislative process with regard to ge-
netic engineering legislation went into full swing, leading
to the adoption of two European Directives in the early
nineties. In this period, the first GM plants were released
in the field for experimental purposes. At the same time,
technology-specific legislation was established in some
Member States (MS) such as Denmark and Germany. Ac-
cording to Gottweis (2005), these legal evolutions at the
EU level also “reflected the new dynamics of the EU po-
litical system after the passing of the 1987 Single Euro-
pean Act, the rise of the European regulatory state, and
the new importance of the environment as a core value in
European policy making”.
To avoid unequal competition and impediments be-
tween and within MS, and to stimulate scientific research
and innovation, the European Commission (EC) pro-
moted the development of a transparent and European-
wide harmonization of GM crop legislations between
MS. This led to the creation of an internal market that
makes the free movement of GM agro-food products pos-
sible in the EU. Other legal objectives included (1) ensur-
ing a high level of protection of human health, animal
health and the environment; (2) enabling consumers and
farmers to exercise eﬀectively their freedom of choice in
the market place; and (3) not misleading consumers and
users (Christoforou, 2004).
Directive 90/220 on the deliberate release into the
environment of genetically modified organisms
From 1990 on, the contained use of GMOs was regulated
by Directive 90/219. Directive 90/220 regulated their de-
liberate release into the environment, covering both the
release for research purposes (part B) and for commer-
cial use as or in products (part C). This regulatory triad
reflects the stepwise commercial process transgenic crops
go through, beginning with experiments under contained
use (e.g. laboratory, greenhouse) through experimental
release, up to the placing on the market.
Once Directive 90/220 was in force, the first market
consents were granted in the EU. The kick oﬀ was given
in 1994 by the approval of the cultivation of the trans-
genic tobacco event ITB1000OX. The first GM product
to be eﬀectively released on the European market was
paste from the Flavr Savr tomato. From February 1996
on, the GM puree destined for human consumption was
sold in the United Kingdom (UK) (Tencalla, 2006). The
last can of GM tomato paste was sold in June 1999
when the retailer excluded GM ingredients from all its
own-brand products (Levidow and Bijman, 2002). With
the approval of the transgenic soybean event GTS40-
3-2 in April 1996, the door was opened for using im-
ported GM crops as food and feed products over the en-
tire EU. Other approvals soon followed: in January 1997,
for instance, the transgenic maize event Bt176 was ap-
proved for all commercial uses. According to both market
consents (96/281 for GTS40-3-2 soybean and 97/98 for
Bt176 maize) no safety reasons required mentioning that
the products had been obtained by genetic modification.
Although market consents were previously granted
for the cultivation of transgenic crops, their cultivation
only started in 1998, after the registration of hybrids de-
rived from Bt176 in the French and Spanish seed cat-
alogues. In 1999, it was the turn for transgenic maize
MON810 varieties. These events indicate that GM crops
destined for various uses gradually penetrated the Euro-
pean market in the mid-nineties (Tab. 1).
Regulation 258/97 on novel foods and
novel food ingredients
Directive 90/220 covered the deliberate release of GMOs
only in generic terms. However, since 15 May 1997, Reg-
ulation 258/97 – the so-called Novel Food Regulation –
removed food products containing, consisting of or pro-
duced from transgenic crops from the Directive’s scope.
This Regulation covered the safety assessment, market-
ing and labeling of a broad category of novel foods in-
cluding those produced by new technologies such as ge-
netic engineering, as well as food without a history of safe
use in the EU. Recommendation 97/618 provided the sci-
entific basis and information needed to compile dossiers
for the marketing of GM food.
Under the Novel Food Regulation, the safety assessment
of GM food was based on the principle of substantial
equivalence between the GM foodstuﬀ and its non-GM
conventional counterpart. The conventional counterparts
were generally taken to have a history of safe use, allow-
ing them to serve as baseline in the comparison of their
chemical composition and phenotypic characteristics to
those of GM foodstuﬀs (Kok and Kuiper, 2003; König
et al., 2004; Levidow et al., 2007; Millstone et al., 1999;
Schenkelaars, 2002).
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Table 1. Overview of commercially authorized GM crop events in the EU per commercial application (pursuant to Directives: 90/220
and 2001/18, and to Regulations: 258/97 and 1829/2003) (Adapted from the Belgian Biosafety Server, http://www.biosafety.be;
European Commission, http://ec.europa.eu/food/food/biotechnology/authorisation/index_en.htm) (January 2007).
Commercial application Crop Transgenic event Main trait Authorization date Notifier
Cultivation Chicory RM3-3, RM3-4, RM3-6 HR, MS 20/05/1996 Bejo-Zaden
Maize Bt1761 HR, IR 23/01/1997 Ciba-Geigy
T251 HR 22/04/1998 AgrEvo
MON8101,2 IR 22/04/1998 Monsanto
Oilseed rape MS1 × RF1 HR, HS 06/02/1996 Plant Genetic Systems
Tobacco ITB1000OX HR 08/06/1994 Seita
Food (all products) Maize Bt176 HR, IR 23/01/1997 Ciba-Geigy
Bt11 HR, IR 19/05/2004 Syngenta
NK603 HR 26/10/2004 Monsanto
GA21 HR 13/01/2006 Monsanto
MON863 IR 13/01/2006 Monsanto
1507 HR, IR 03/03/2006 Pioneer Hi-Bred International,
Mycogen Seeds
Soybean GTS40-3-2 HR 03/04/1996 Monsanto
Food (only crop Maize MON810 IR 06/02/1998 Monsanto
derivatives and products T25 HR 06/02/1998 AgrEvo
made with crop Bt11 HR, IR 06/02/1998 Novartis
derivatives e.g. oil) MON809 HR, IR 23/10/1998 Pioneer
Oilseed rape Topas19/2 HR 24/06/1997 AgrEvo
MS1 × RF1 HR, HS 24/06/1997 Plant Genetic Systems
MS1 × RF2 HR, HS 24/06/1997 Plant Genetic Systems
GT73 HR 21/11/1997 Monsanto
Falcon GS40/90 HR 08/11/1999 Hoechst Schering, AgrEvo
Liberator L62 HR 08/11/1999 Hoechst Schering, AgrEvo
MS8 × RF3 HR, HS 24/04/2000 Plant Genetic Systems
Cotton RRC1445 HR 19/12/2002 Monsanto
IPC531 IR 19/12/2002 Monsanto
Feed, import, Maize Bt176 HR, IR 23/01/1997 Ciba-Geigy
industrial processing T25 HR 22/04/1998 AgrEvo
Bt11 HR, IR 22/04/1998 Novartis Seeds
MON810 IR 22/04/1998 Monsanto
NK603 HR 19/07/2004 Monsanto
MON863 IR 08/08/2005 Monsanto
1507 HR, IR 03/11/2005 Pioneer Hi-Bred International,
Mycogen Seeds
MON863 ×MON810* IR 16/01/2006 Monsanto
Soybean GTS40-3-2 HR 03/04/1996 Monsanto
Oilseed rape Topas19/2 HR 22/04/1998 AgrEvo
GT73 HR 31/08/2005 Monsanto
Abbreviations: HR = herbicide resistance; HS = hybrid system; IR = insect resistance; MS = male sterility.
1 Genetically modified varieties derived from a transgenic event included in (a) national catalogue(s) of varieties of agricultural plant
species (France: 9 Bt176 and 6 MON810 hybrids, Germany: 5 MON810 hybrids; Spain: 36 MON810 hybrids; the Netherlands:
1 T25 hybrid).
2 Genetically modified varieties derived from a transgenic event included in the common EU catalogue of varieties of agricultural
plant species (31 MON810 varieties).
* Except for feed uses.
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Nonetheless, that conventional food products are gen-
erally safe is merely an assumption. Indeed, very few of
them have been subjected to toxicological studies. Also,
the degree of diﬀerence necessary to determine when the
substance of the GM foodstuﬀ ceases to be acceptably
equivalent to the conventional counterpart was not de-
fined clearly. Because of this, the substantial equivalence
principle remained open to a diversity of interpretations,
making its implementation in practice rather complicated
and contentious. Other critical points were uncovered.
First, substantial equivalence was often misperceived as
the endpoint of a safety assessment, rather than the start-
ing point. Initially, no risk assessment was required when
a GM food was substantially equivalent. Second, it ap-
peared to be diﬃcult to predict the biochemical or tox-
icological eﬀects of a GM food from its chemical com-
position. Third, complaints were made that it was not an
absolute safety assessment in itself: not all the potentially
harmful components are assessed, since some of these
components may not be associated with the genetic mod-
ification. Fourth, a comparative safety assessment could
not be done if no appropriate comparator is identified,
requiring a comprehensive safety and nutritional assess-
ment of the GM foodstuﬀ per se.
Following the growing criticism of substantial equiv-
alence as a basis to evaluate GM food, the principle was
interpreted more strictly over time. Only products with-
out detectable traces of the new DNA or protein could be
notified under the simplified procedure, whereas products
not satisfying these criteria underwent a full risk assess-
ment under the normal authorization procedure.
With the Novel Food Regulation, foodstuﬀs were sub-
jected to specific labeling requirements, thereby comple-
menting Directive 97/4 on the labeling, presentation and
advertising of foodstuﬀs. The consumers’ right to be in-
formed of any characteristic or food property was ex-
tended to novel food or food ingredients that diﬀered ma-
terially from existing ones, hence allowing consumers to
make an informed choice on the basis of their own values.
The modified characteristics and the method used thus
had to be mentioned on the label. Labeling was also re-
quired when (1) the novel food contains material that is
not present in an existing equivalent foodstuﬀ, and which
may have implications for the health of certain sections
of the population; and when (2) the presence of such ma-
terial gives rise to ethical concerns (Christoforou, 2004).
Although the precise meaning of these ethical concerns
was not clarified, they were received in terms of peo-
ple perceiving GM agro-food products as “unnatural”, as
“a violation of the sanctity of species”, as “disrespect-
ful for nature”, or as “incompatible with organic farm-
ing” (Streiﬀer and Hedemann, 2005; Streiﬀer and Rubel,
2004).
According to the labeling provisions of the Novel
Food Regulation, labeling was not required when a
genetically engineered raw material had been treated
technically in such a way that neither the new DNA nor
the protein could be detected in the final product. Since
May 1997, processed oil from GM oilseed rape, maize
and cotton, and processed food and food ingredients de-
rived from GM maize have been notified as being sub-
stantially equivalent and thus approved for human con-
sumption under the simplified procedure of the Novel
Food Regulation. Moreover, labeling did not apply to
foodstuﬀs already used for human consumption in the
EU prior to the establishment of the Novel Food Regu-
lation. Already marketed foodstuﬀs, such as GTS40-3-2
and Bt176, were not considered as novel. Nor did the EC
see reasons to label these products judged to be safe as
being obtained by genetic modification. However, with
the adoption of Regulations 1813/97 and 1139/98, the la-
beling of GTS40-3-2 and Bt176 foodstuﬀs also became
compulsory. From that moment on, the label literally had
to contain the words ‘produced from GM soybean’ or
‘produced from GM maize’ when the new protein or
transgene were detectable in the end product intended
for consumption. With Regulation 50/2000, the labeling
provisions were extended to additives and flavorings that
have been genetically modified or that have been pro-
duced from a GMO.
DE FACTO MORATORIUM
ON THE COMMERCIALIZATION OF NEW
GM CROP EVENTS
GM crops were initially restricted to and confined in re-
search and development laboratories. However, they soon
gained presence in agricultural fields, in the supply chains
and – to a lesser extent – on supermarkets’ shelves and on
consumers’ plates. They directly and physically entered
the public sphere, which largely amplified the opposition
to GM crops in the EU.
The growing opposition was played out in vari-
ous arenas (Bonneuil et al., in press; Gruère, 2006;
Kalaitzandonakes and Bijman, 2003; Lassen et al., 2002;
Levidow and Bijman, 2002; Levidow et al., 2005). In
1996, non-governmental organizations (NGOs) block-
aded shipments containing GM soybean or maize, be-
cause the providers decided not to segregate GM and non-
GM agro-food products. Under the influence of intensive
NGO campaigns, consumers boycotted GM agro-food
products. Major supermarket chains excluded GM ingre-
dients from their own-brand food products, as a mea-
sure to respect consumers’ preferences. The food indus-
try adopted negative labeling to guarantee the absence
of GM material in foodstuﬀs, and the retail food chains
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launched bans against products from animals reared on
feed produced from GM crops. Portugal withdrew the
two inscribed GM maize hybrids from its seed catalogue,
prohibiting their further cultivation on the Portuguese ter-
ritory.
The assessment of market notifications led to se-
rious regulatory-expert disputes between European and
national safety assessment bodies. Conflicting positions
were at play concerning the kinds of risk to assess or
to ignore, the reliability of scientific evidence, the base-
line of comparison to use for assessing the severity and
acceptability of risk, and about the means of managing
uncertain risks (Carr, 2002). Value judgments, which are
required to characterize risks and to determine the ac-
ceptability of health and environmental impacts, diﬀered
among EU institutions and MS. At the EU level, these
issues were treated generally as technical ones, thereby
downplaying long-term adverse eﬀects and socio-cultural
values underlying science, whereas some MS applied rel-
atively broader precautionary accounts by defining risk
in broader ways (Levidow, 2001). Consequently, some
MS invoked national safeguard clauses to provisionally
restrict or prohibit the use and/or sale of authorized GM
agro-food products on their territory. In August 2000, for
instance, the Italian government suspended the sale of
products derived from four GM maize events, approved
under the simplified procedure of the Novel Food Reg-
ulation. The government’s opinion was that substantial
equivalence had not been properly shown, requesting a
full risk assessment (Levidow et al., 2007). Like some
MS, various NGOs defined risk broadly, linking it fre-
quently to a sustainability discourse.
Some scientists, regulators and NGOs started to ques-
tion the appropriateness of small-scale, short-term and
strictly confined field trials in forecasting the risks un-
der real agricultural situations over a longer time frame
(Firbank et al., 2005), as well as the domination of
biotechnologists in regulatory and expert arenas (Bon-
neuil et al., in press).
At the June 1999 meeting of the Environmental
Council, Austria, Denmark, France, Greece, Italy and
Luxembourg decided not to accept new market consents
of new GM crop events as long as the existing regula-
tory frame was not revised. This de facto moratorium
hindered the commercialization of GM agro-food prod-
ucts in the EU. First, stronger legislations were requested,
with more stringent, transparent and precautionary risk
assessment criteria, in order to improve the safety as-
sessment of GM agro-food products. Legal clarifications
were also requested on environmental liability, in case of
environmental damage caused by the deliberate release
of GM crops. These societal demands focused on the
availability of safe GM agro-food products to consumers,
and the protection and maintenance of the environment
and its biodiversity. Second, the implementation of la-
beling, traceability, co-existence and public registers was
requested to respect the consumers’ and farmers’ free-
dom of choice, and to provide information about GM
agro-food products to the public (Brom, 2000; Mepham,
2000; Nielsen and Faber, 2002; Paula and van den Belt,
in press).
The complicated legal situation, combined with the
negative public perception of GM crops and the system-
atic destruction of field trials by activists, resulted in the
cutting-down and/or holding-oﬀ of research activities in
plant biotechnology. Despite favorable risk assessments,
the acquisition of a permit for field trials was no longer
obvious. As a result, the number of field trials – being
the intermediate step when applying for market consent
– showed a drastic drop of 76% between 1998 and 2001
(Lheureux and Menrad, 2004). Notifiers lost their confi-
dence in existing authorization processes, and many re-
search and development departments were relocated to
other world areas (Mitchell, 2003; Tencalla, 2006).
From this period on, public attention to the potential
adverse impact of GM crops was nourished by various
events: statements of opposition from the UK’s Prince
Charles, the scientist Pusztai announcing on the British
television that rats fed with GM potato – modified to
express snowdrop bulb lectin – suﬀered adverse health
eﬀects, the findings of Losey and colleagues who re-
ported that monarch butterfly larvae were susceptible to
harm from Bacillus thuringiensis (Bt) toxins when fed
with pollen of Bt maize, the various actions of the orga-
nized network of trolley watchers directed towards GM
foodstuﬀs and supermarkets selling these products, and
the increasing media coverage reflecting the bold rhetori-
cal and metaphorical discourses of both GMO opponents
and proponents (Cook et al., 2006; Petersen, 2005). A
series of scandals on food safety amplified the suspi-
cion of the public towards policy makers, industry and
scientists, and extended national regulatory diﬀerences.
Broader ethical and socio-economical concerns entered
the GM debate where risk concerns occupied a promi-
nent position, especially in France, under the influence of
the anti-globalization leaders (Heller, 2002; Marris et al.,
2005). Questions relating to, e.g., the agronomic and
socio-economic relevance of transgenic crops, their use-
fulness and sustainability, the type of food and agriculture
wanted, the standardization of food, the independence of
public research became more prominent. Later, the GM
controversy also moved to local scenes, with local author-
ities and regional governments voting bans on the cultiva-
tion of transgenic crops on their territory. Actors that had
a muted voice in the GMO debate, succeeded in forging
coalitions, leading to the creation of an impressive num-
ber of GM-crop-free zones all over the EU. This move-
ment emphasized a request of many regional and local
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Table 2. Historical overview and scope of the European regulatory frame coping with GM crops from 1990 onwards (using the
adoption dates of legal texts).
Year Field trials, 
cultivation,
import, 
processing
Feed Food Labeling Traceability Co-existence 
liability 
Organic
farming 
     022/09 D 0991
1991        R 2092/91 
1992         
1993         
1995         
1996         
1997   R 258/97 R 1813/97     
1998    R 1139/98     
1999 R 50/2000 
2000 R 49/2000 R 1804/1999
2001 D 2001/18 D 2001/18 
2002 R 178/2002 R 178/2002 R 178/2002 
2003 R 1829/2003 R 1830/2003 D 2001/18 
2004 R 641/2004 R 65/2004; R 641/2004 D 2004/35 
2005         
2006         
Environmental 
Abbreviations: D = Directive; R = Regulation.
Grey zone: de facto moratorium on the commercialization of new GM crop events.
authorities to decide whether GM crops can be cultivated
on their territory. With these evolutions, the inadvertent
mixing of GM and non-GM agro-food products and the
co-existence between cropping systems emerged as addi-
tional issues in the GMO debate (Levidow and Boschert,
in press).
RESTYLING OF THE EUROPEAN REGULATORY
FRAME ON GM CROPS
During the de facto moratorium various waves of insti-
tutional reform led to a gradual revision of the existing
legislations and to the creation of new EU institutes. Both
general and product-specific legislations were introduced
in order to replace or amend older ones. Through this,
specific values, norms, criteria and principles already
present in the regulatory frame were strengthened and
harmonized, whilst new ones were implemented. These
regulatory revisions are discussed below in more detail
in order to pinpoint the accompanying change in values
(Tab. 2).
Restyling I: Directive 2001/18: a new view on
the deliberate release into the environment
of genetically modified organisms
On 17 October 2002, after years of preparation and
discussion within the European Council and European
Parliament, Directive 2001/18 replaced the older Direc-
tive 90/220. This Directive took into account the latest
scientific research and international legal developments
(Christoforou, 2004). With it, the precautionary princi-
ple was explicitly adopted as a guide, the risk assessment
criteria were broadened to include direct, indirect, imme-
diate, delayed and cumulative long-term adverse eﬀects,
post-market monitoring became obligatory, the need for a
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common methodology for the environmental risk assess-
ment was established, the phasing out of certain antibi-
otic resistance marker genes was introduced, the existing
labeling provisions applying to GM foodstuﬀs were ex-
tended to all the marketed products containing GMOs,
the general concept of traceability at all stages of com-
mercialization was introduced, the transparency in the
decision-making process was increased, the consultation
of the public became mandatory in the authorization pro-
cedure, the possible consultation of an ethics committee
was confirmed, and the implementation of national culti-
vation registers that record the locations where GM crops
have been cultivated was required. In the remainder of
this chapter, several of these themes are discussed in more
detail, starting with the precautionary principle.
Explicit adoption of the precautionary principle (PP)
in the new Directive
Compared to its predecessor, a major shift in Directive
2001/18 is the explicit adoption of the PP as a guide. The
Directive states that (1) “the PP has been taken into ac-
count in the drafting of the Directive and must be taken
into account when implementing it”; and that (2) “MS
shall, in accordance with the PP, ensure that all appro-
priate measures are taken to avoid adverse eﬀects on hu-
man health and the environment, which might arise from
the deliberate release or the placing on the market of
GMOs”. With its increasing acceptance as a general prin-
ciple in (inter)national law, various interpretations have
been given to the PP; some authors have even defined the
PP as an ethical principle that risk assessors and risk man-
agers should adopt in the face of scientific uncertainty
(Carr, 2002; Jensen, 2002). Based on a number of dif-
ferent versions of the PP, Sandin (1999) extracted four
common dimensions of the PP and expressed them in
the following if-clause: “if there is (i) a threat, which is
(ii) uncertain, then (iii) some kind of action (iv) is manda-
tory”. In this if-clause, the threat dimension concerns pos-
sible damages or harm of an activity, which can be quali-
fied as serious, significant or irreversible. The uncertainty
dimension expresses the need for scientific uncertainty to
take precautionary measures, and thus relates to the limits
of scientific knowledge on suspected risks. While the ac-
tion dimension rather concerns possible responses to the
uncertain threat, the final command dimension focuses on
the way in which action is prescribed (Sandin, 1999).
In the following section we will address how these
dimensions are reflected in the legal criteria created by
Directive 2001/18 and in the “Communication on the PP”
issued by the EC (CEC, 2000), and how these dimensions
are translated in practice.
(i) Threat dimension: In Directive 2001/18, qualifying
adjectives referring to risks are only used in the preamble
and the guidance note that supplements Annex II. In a risk
analysis done in accordance with the provisions of Direc-
tive 2001/18, judgments are made about what counts as
a harmful impact. When an eﬀect is defined as adverse
or harmful it implies that the deterioration in quality of a
particular environmental subject exceeds a certain chosen
level of environmental protection (CEC, 2000). Directive
2004/35 on environmental liability here defines environ-
mental damage as “a measurable change in a natural re-
source or measurable impairment of a natural resource
service, which may occur directly or indirectly”. It is the
severity of a potential adverse eﬀect combined with the
level of scientific uncertainty that triggers precaution.
In risk analysis, one thus first has to define the envi-
ronmental subjects considered relevant to assess/protect
or considered valuable for society. The conservation ob-
jectives set by Directive 2001/18 are of a general nature,
aiming at a high level of protection of human health and
the environment. Despite this general nature, the previous
environmental risk window is broadened, by requiring the
assessment of potential direct, indirect, immediate, de-
layed and cumulative long-term adverse eﬀects. Conse-
quently, more agro-ecological expertise is included, and
a set of new subjects implicitly enters the scope of the
environmental risk assessment. Previously, for instance,
indirect adverse eﬀects on farmland biodiversity caused
by the use of non-selective herbicides on GM crops fell
beyond the remit of Directive 90/220, because they were
considered to be agronomic issues. However, MS that pri-
oritized the protection of farmland biodiversity or that
aimed at reducing agro-chemical usage to ensure the use
of ground water as drinking water already included this
issue in their assessments (Levidow, 2001). Nowadays, it
is considered to be a statutory criterion (ACRE, 2004a,
2005; BAC, 2004).
After identifying the deterioration in quality of a par-
ticular subject, one has to define whether it exceeds a
certain chosen level of environmental protection (CEC,
2000). The baseline against which this change is com-
pared allows determining its severity and acceptability.
According to EC standards, the most dominant form of
agriculture is considered as the baseline for comparison.
It means that an adverse eﬀect due to the use of a trans-
genic crop is acceptable as long as the eﬀect remains
within the range of variability observed in conventional
agriculture.
Although such a comparative approach – relying on
the concept of familiarity – is a useful tool in the risk
analysis of GM crops, it does show some weaknesses, due
to a rather uncritical conception of conventional farming.
Despite the general assumption that conventional farm-
ing is safe, it is known that biodiversity associated with
many conventional crops is declining due to, for instance,
the increased use of fertilizers and pesticides and/or the
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shift from spring to winter cropping (Chamberlain et al.,
2000; Robinson and Sutherland, 2002). Also the Farm
Scale Evaluations have shown that diﬀerences in the im-
pact on wild flora and fauna can be greater between dif-
ferent conventional crops (e.g. between maize and oilseed
rape) than between a GM herbicide resistant crops and
its non-GM herbicide susceptible counterpart (Firbank
et al., 2005). In this context, a comparative approach is
still flawed because it may permit the use of a harm-
ful GM crop on grounds that the comparator also causes
harm. It may also be the case that less harm is tolerated
for GM crops, whereas conventional practices are equally
or more harmful. For example, although a conventionally
bred herbicide resistant crop could generate similar im-
pacts as the GM one, it is unlikely that it would be as-
sessed (ACRE, 2006; Chassy et al., 2003).
Another diﬃculty is translating statistical significant
adverse eﬀects into significant biological or ecological ef-
fects: a reduction in soil biodiversity does not necessarily
cause a decrease in soil function (Lilley et al., 2006).
Also, the assessment of the wider impact of GM
crops and their associated agricultural practices is not
promoted. This is because a harm-oriented approach is
followed rather than a goal-oriented one (Deblonde and
du Jardin, 2005). As such, single GM crops are assessed,
but not the whole agricultural system. Within a wider as-
sessment frame, a potential risk may be traded against
potential benefits. However, Directive 2001/18 currently
does not permit a GMO to progress to a sustainability as-
sessment if a single biologically significant harmful envi-
ronmental eﬀect is detected, irrespective of any potential
environmental benefits that it could oﬀer (ACRE, 2006).
Finally, it has been argued that judgments about the
acceptability of impacts should not only be based on con-
ventional farming, but also on organic or integrated farm-
ing in order to strike a new balance between agricultural
production and biodiversity. In Austria, Germany and
Italy, for instance, GM agro-food products are considered
to constitute a threat to organic or integrated agriculture
or to local traditional products, and thus to national values
(Levidow, 2001). However, also this option is not easy to
implement: applying diﬀerent baselines among European
institutions and MS has already led to contentious po-
sitions on the acceptability of risks. This illustrates that
various accounts of precaution are identifiable at the EU
level (Levidow et al., 2005). Depending on the accounts
taken, some MS not only consider dangerous eﬀects, but
also encompass undesirable ones in risk assessments.
(ii) Uncertainty dimension: According to the EC, “the
absence of proof of the existence of a cause-eﬀect rela-
tionship”, “a quantifiable dose/response relationship” or
“a quantitative evaluation of the probability of the emer-
gence of adverse eﬀects following exposure” can trig-
ger precautionary measures (CEC, 2000). Depending on
the precautionary accounts taken, EU practice shows that
precautionary measures were taken not only when the sci-
entific plausibility of the suspected risk is to some ex-
tent verifiable, but also when there were suspicions or in-
adequate evidence about uncertain risks (Levidow et al.,
2005).
Through the adoption of the PP in Directive 2001/18,
it is recognized that risk assessments are limited by a de-
gree of scientific uncertainty, ignorance, indeterminacy,
ambiguity and inconclusiveness, and that decisions must
be made acknowledging that these shortcomings may not
be resolved (Carr, 2002; CEC, 2000; Hoﬀmann-Riem and
Wynne, 2002; Krayer von Krauss et al., 2004; Sanvido
et al., 2005; Wandall, 2004). This is also the tenor of
the EC guidance note for the environmental risk assess-
ment (2002/623) that supplements Annex II of Directive
2001/18: it recommends “describing uncertainties, clar-
ifying the assumptions, extrapolations and predictions
made, explaining the diﬀering points of view, and dis-
cussing the known limits”. In this respect, there is an at-
tempt to render explicit the value judgments and pluralis-
tic viewpoints occurring in, as well as the limitations of
risk assessment. These clarifications are intended to allow
risk managers to judge whether the factual basis of the
risk assessment is suﬃciently reliable to act upon. So far,
these clarifications have in fact remained implicit at the
EU level. Levidow and Carr (in press) observed that the
scientific opinions of the European Food Safety Authority
(EFSA) “generally have framed scientific uncertainties in
such a way that they can be resolved by extra information,
or can be readily managed, or can be deemed irrelevant to
any risk”. Moreover, the EFSA harmonized expertise to
provide consensual objective opinions, downplaying di-
verse views and limitations (Levidow and Carr, in press).
This trend may be explained by the fact that risk man-
agers may no longer receive opinions that are straightfor-
ward, and that expert disagreement about the reliability of
scientific evidence for risk assessments may reduce pub-
lic credence in science-based policy.
(iii) Action dimension: The idea of responding to an
uncertain threat is generally translated in terms of bring-
ing restrictions to the free movement of GM agro-food
products, provided that these are “proportional to the de-
sired level of protection”, “non-discriminatory in their ap-
plication”, “consistent with measures already adopted in
similar circumstances”, “consider the costs and benefits
of both action and lack of action”, and “consider develop-
ments in scientific knowledge” (CEC, 2000). The heated
debates about the potential occurrence of feral oilseed
rape populations along transportation routes due to grain
spillage – induced by the assessment of the notification
that covered the import of the oilseed rape GT73 event –
illustrated divergent positions on how to manage uncer-
tain risks. The potential occurrence of feral oilseed rape
Environ. Biosafety Res. 5, 3 (2006) 135
Y. Devos et al.
populations was judged as unacceptable by some MS, de-
manding specific controls to prevent spillage and requir-
ing its monitoring, whilst others and the EFSA found no
grounds for any risk (Levidow, 2006).
Under Directive 2001/18, mandatory environmental
post-market monitoring (PMM) has been chosen as the
privileged precautionary measure to cope with scientific
uncertainties. Generally, monitoring relies on checking if
certain standards are met, examining potential changes
with respect to an established baseline, and/or reducing
the scientific uncertainties that were identified in risk as-
sessment. Since not all potential scientific uncertainties
can be assessed prior to release, PMM is relevant, al-
though further research may not always overcome these
uncertainties.
Annex VII of Directive 2001/18 and its supplement-
ing guidance note (2002/811) describe an environmen-
tal monitoring plan consisting of case-specific monitoring
and general surveillance: general surveillance is always
obligatory, whilst case-specific monitoring is imposed on
a case-by-case basis (EFSA, 2006a). Due to the diﬀer-
ent objectives between case-specific monitoring and gen-
eral surveillance, their underlying concepts diﬀer (ACRE,
2004b; EFSA, 2006a; Sanvido et al., 2005). In the for-
mer, foreseen potentially adverse changes are related to
specific causes (known unknowns), whereas in the lat-
ter the detection of unforeseen changes without known
specific cause (unknown unknowns) is aimed at. Case-
specific monitoring is mainly triggered by scientific un-
certainties that were identified in risk assessment. Hence,
a hypothesis is established that can be tested on the basis
of the newly collected data. In contrast, in general surveil-
lance, the general status of the environment that is asso-
ciated with the uses of GM crops is monitored without
any preconception. Here, eﬀects – including cumulative
long-term eﬀects – that were not anticipated in the en-
vironmental risk assessment are sought. Then, it has to
be determined whether the unusual eﬀect detected is ad-
verse, and whether it is associated with the use of a trans-
genic crop.
In the elaboration of its guidance note on environ-
mental PMM, the EFSA consulted a wide range of ac-
tors (EFSA, 2006a). From these discussions, it arose that
the approaches and principles of environmental PMM are
diversely interpreted, reflecting diﬀerent precautionary
accounts. According to narrow accounts, PMM is only
justified until additional scientific evidence is obtained
that allows a more complete risk assessment. This oﬀers
the possibility to define whether the risk assessment has
changed or whether risk management should be changed.
Within broader precautionary accounts, research is not
only needed to fill data gaps, but also to improve the
bases of available knowledge. On the basis of Annex VII
of Directive 2001/18, some plead that monitoring should
be done to confirm the correctness of any assumption on
the occurrence and impact of potential adverse eﬀects of
the GMO or its use made in the environmental risk as-
sessment. However, the EFSA emphasized that this goes
far beyond the remit of the PP, since monitoring plans
would not only cover the ‘known unknowns’, but also the
‘known knowns’. PMM aims at elucidating the ‘known
unknowns’ related to potentially harmful risks in order to
confirm or refute uncertain assumptions made in the en-
vironmental risk assessment, whereas an adverse ‘known
known’ can be managed preventively to reduce the an-
ticipated risk to an acceptable level. The ‘nice to know’
versus ‘need to know’ divergences are also reflected in
the demands to apply an unconditionally surveillance of
all areas exposed to GM crops or likely to be aﬀected
by their cultivation, to conduct intensive biosafety pro-
grams, to require a null hypothesis in general surveil-
lance, and/or to establish comprehensive lists of protec-
tion goals (EFSA, 2006a).
Where any environmental damage was observed, the
output of PMM could be coupled to environmental lia-
bility, in order to trigger remedial measures and liability.
However, Karlsson (2006) doubts that “environmental li-
ability will have any meaning when it comes to the ordi-
nary use of GM crops, since the environmental liability
Directive gives exceptions for authorized activities”.
(iv) Command dimension: Directive 2001/18 men-
tions that “MS shall, in accordance with the PP, en-
sure that all appropriate measures are taken to avoid ad-
verse eﬀects on human health and the environment, which
might arise from the deliberate release or the placing on
the market of GMOs”.
As mentioned above, the PP has been explicitly adopted
in the new Directive 2001/18. Nonetheless, before, an im-
plicit precautionary approach was already applied. This
can be demonstrated through diﬀerent aspects of the older
regulatory frame.
For example, the iterative process of risk analysis al-
ways has been precautionary in the sense that its deci-
sions are temporary, reversible and adaptable in the light
of new information that becomes available. With the ad-
vent of new information, it had to be defined whether the
risk assessment has changed, or whether risk manage-
ment should be changed. Under Directive 2001/18, this
duty of re-examination has been strengthened by limit-
ing the duration of market consent to a maximum of ten
years.
A precautionary approach also was reflected in the
right of a MS to provisionally restrict or prohibit the use
and/or sale on its territory of an approved GMO. Even
more, some MS already applied the PP by enforcing mon-
itoring activities in the face of scientific uncertainties. In
France, for instance, research on vertical gene flow and its
agro-ecological consequences was funded (Marris et al.,
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2005), whereas in the UK, harm to farmland biodiversity
caused by herbicide use was assessed in the Farm Scale
Evaluations (Oreszczyn, 2005).
Finally, entire categories of products for which there
was no prior evidence of harm were a priori regulated,
to guarantee the protection of human health and the
environment, and to predict and avoid harm (Levidow,
2001). The burden of proof to demonstrate biosafety prior
to use was in the hands of those who claim that the activ-
ity in question causes no adverse eﬀects. Notifiers are in
charge of providing a risk assessment, which is gener-
ally done (1) in accordance to the latest standards of sci-
entific knowledge; (2) on a case-by-case basis, because
few generic judgments can be made about the safety and
impact of GM crops; and (3) step-wise – according to
a tiered approach – where the assessment increases in
complexity and realism based on the knowledge gained
during previous steps. Subsequently, MS evaluate the sci-
entific quality of the submitted notifications, request addi-
tional information, take steps to ensure that human health
and the environment are protected, and guarantee that
the risks associated with the use of an authorized GMO
are considered to be very low. In this process, some MS
requested more reliable or complete information, and/or
challenged the available evidence, especially on molecu-
lar characterization or toxicological tests (Levidow et al.,
2005).
The overall precautionary character of the EU leg-
islation on GM crops – in both its implicit and explicit
form – has been doubted, because “ignorance and uncer-
tainty are poorly dealt with, complex social and politi-
cal judgments are made by experts in ways that are not
transparent, and there is little opportunity for public par-
ticipation” (Karlsson, 2006; Mayer and Stirling, 2002).
Moreover, some prescribe an interpretation of precaution
that is explicitly linked to the ideal of sustainable devel-
opment (ACRE, 2006; Deblonde and du Jardin, 2005).
A common methodology for environmental risk
assessment (ERA)
The objectives of the ERA are to identify adverse ef-
fects of GMOs and to measure and predict their serious-
ness, as well as their likelihood of occurrence. Before the
new Directive, ERA frameworks varied considerably in
the number and definition of particular action steps and
in the terminology used to describe these steps. Experts
from diﬀerent disciplines understood the conceptual basis
for risk assessment diﬀerently or confused the successive
steps (Hill, 2005; Hill and Sendashonga, 2003). For in-
stance, when transgene flow towards certain wild/weedy
relatives is considered as a problem in itself, the risk as-
sessment will be limited to the exposure step in order to
estimate vertical gene flow. However, the estimation of
vertical gene flow per se is not generally considered to be
a complete risk assessment: it requires not only an evalu-
ation of exposure, but also the evaluation of the potential
adverse consequence(s) resulting from vertical gene flow
(Chapman and Burke, 2006; Hails and Morley, 2005).
To avoid further confusion and to promote a common
understanding of the ERA, the guidance note (2002/623)
that supplements Annex II of the new Directive describes
a common conceptual basis and methodology for the
ERA. An ERA now consists of six successive steps:
(1) characteristics which may cause adverse eﬀects are
identified; (2) potential consequences of each separate
adverse eﬀect are estimated and evaluated; (3) likelihood
of occurrence of each identified potential adverse eﬀect is
evaluated; (4) risk posed by each identified characteristic
of the GMO is estimated; (5) management strategies are
chosen and applied; and finally; and (6) overall risk of the
GMO is determined.
Despite this conceptual and methodological harmo-
nization, the practical definition of adverse eﬀects, which
proved to be contentious at EU level, remained unad-
dressed.
Phasing out of antibiotic resistance marker (ARM) genes
In the transformation process of GM crops, ARM genes
are commonly used to enable the selection of transformed
plant cells and/or of the vector constructs used. With
the cumulative and large-scale release of diﬀerent GM
crop events containing ARM genes, an unwanted increase
in existing levels of antibiotic resistance in microorgan-
isms was feared, due to its possibility to compromise
therapy. However, risk assessments have generally con-
cluded that (1) the frequency of horizontal gene trans-
fer from GM crops containing ARM genes towards mi-
crobial populations is very low; (2) the hazard arising
from any such gene transfer is, at worst, slight; but that
(3) their use should be strongly discouraged when they
could compromise the use of clinically relevant antibi-
otics (Bennett et al., 2004; EFSA, 2004a; Goldstein et al.,
2005; van den Eede et al., 2004).
Following this line of arguments, and in accordance
with the PP, Directive 2001/18 requires the phasing out of
genes encoding resistance to antibiotics in use for med-
ical or veterinary treatment by 2005 for commercial re-
leases, and by 2009 for research purposes, provided that
the genes have adverse eﬀects on human health and the
environment. NGOs and some MS welcomed this turn in
regulatory policy on ARM genes; they judged the possi-
bility of ARM gene transfer as unacceptable. Relying on
broader precautionary accounts, they requested the com-
plete elimination of ARM genes. On these grounds, many
notifications for field trials were rejected in the EU.
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Following the various objections raised by MS re-
garding the presence of ARM genes in notified GM agro-
food products, the EFSA was consulted to provide clear
guidance. Considering their clinical importance and the
availability of alternatives, ARM genes were categorized
into three groups by the EFSA. The first group contained
ARM genes that are already widely distributed in mi-
croorganisms in the environment, and which confer re-
sistance to antibiotics of minor or no clinical relevance,
such as nptII, which confers kanamycin resistance. Since
there is no rationale for inhibiting or restricting the use
of these ARM genes, the EFSA judged their use in GM
plants as permissible. The ARM genes contained in the
other two groups conferred resistance to antibiotics that
are clinically relevant or highly relevant (e.g. strepto-
mycin, tetracycline). Their use in GM plants destined for
experimental or commercial release should be restricted
or prohibited (EFSA, 2004a).
Following the EFSA opinion, Spain recently with-
drew the five inscribed Bt176 hybrids from its seed cat-
alogue: the ARM gene present in Bt176 – ampicillin re-
sistance – belongs to the group of ARM genes whose use
had to be restricted to field trials. The French seed cata-
logue still counts nine Bt176 hybrids, but these have not
been cultivated commercially since 1999. The reason is
that transgene expression in these hybrids drops after pol-
lination, reducing the protection against the targeted pest
insects (Tab. 3). Since the more stringent criteria adopted
by some MS were not acknowledged in the EFSA opin-
ion, they maintained their objections to the presence of
ARM genes in notified GM agro-food products.
Public consultation and information
Under Directive 2001/18, the consultation of the pub-
lic and other actors during the authorization procedure
also became mandatory. This is based on the assumption
that public consultation enables risk managers to make
better informed decisions, since they will better under-
stand divergent interpretations of uncertainties and the
underlying values held by diﬀerent actors (Irwin, 2006;
Karlsson, 2003b; Schibeci et al., 2006). For commercial
releases, this consultation is organized at the European
level, whereas it is organized at the national level for ex-
perimental releases. In both cases, the Summary Notifica-
tion Information Format (SNIF) serves as the main source
of information.
Unfortunately, the template and content of the SNIF
did not develop along with the changes made in Directive
2001/18. Under the old Directive 90/220, the SNIF was
only exchanged between MS as an early warning system
to rapidly identify potential adverse risks: MS demanded
technical and summarized information. Nowadays, the
same SNIF is made available to the public, but it does
not address societal concerns.
In response to this weakness, in Belgium, the ‘public
files’ were institutionalized. Under guidelines specifically
designed for the compilation of public files, notifiers were
recommended to address questions about the added value
of the envisaged releases and the technology used, about
arguments of choice of technology, and about weighing
alternatives. Emphasis was put on the semantic accessi-
bility of these public files.
Despite these eﬀorts, and despite the fact that public
comment is currently allowed for, only those criteria in-
cluded within the prescribed risk assessment of the Direc-
tive are taken into account in market decisions (Karlsson,
2006; Mayer and Stirling, 2002). Hence, the tendency to
overlook societal issues in the authorization procedure
seems to continue, giving European public consultation a
mere symbolical or ritual character (Irwin, 2006). In case
of experimental releases, the situation is somewhat diﬀer-
ent: MS retain a larger competence and, generally, apply
broader precautionary accounts. Some MS used this flex-
ibility to create room to take public comments seriously.
Consultation of an ethics committee
Another new element in Directive 2001/18 is that the
Commission’s European Group on Ethics in Science and
New Technologies can evaluate ethical issues of a general
nature. This Group is an independent, pluralistic and in-
terdisciplinary authority. This possibility oﬀers an ‘open-
ing’ to address some of the ethical concerns underlying
public skepticism towards GM agro-food products. Still,
it needs to be said that, by its recommendations the con-
sultation envisaged is not supposed to stop or delay the
consent procedure or to change the consent (Jensen et al.,
2003; Madsen and Sandøe, 2005). Already in 1995, the
Group provided an opinion on the ethical aspects of the
labeling of food derived from modern biotechnology. Ac-
cording to this opinion, the primary ethical imperatives
applying to marketed GM agro-food products relate to
their safety, labeling, benefits and free movement in the
EU (EGE, 1995).
Yet, MS retain a competence regarding ethical issues
because the Directive states that (1) “respect for ethical
principles recognized in a MS is particularly important”;
(2) “MS may take ethical aspects into consideration when
GMOs are deliberately released or placed on the market
as or in products”; and that (3) “MS should be able to
consult any committee they have established with a view
to obtain advice on the ethical implications of biotech-
nology”. Due to a lack of concrete substantial and/or pro-
cedural recommendations, some MS doubt the sincerity
of these statements. Other MS explicitly address ethical
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Table 3. Numbers of GM maize varieties registered in or withdrawn from national catalogues and/or common EU catalogue of
varieties of agricultural plant species and area cropped with GM maize in the EU (data adapted from personal communications of
Bartsch D, Carvalho P, Cerovska M, Fresno Ruiz A, Grevet A, Hervieu F, Köller M, Roda Ghisleri L and Tencalla F, and from the
consultation of national and the common EU catalogue(s) up to January 2007).
Year Event Number of registered (+) or withdrawn (−) varieties (Var) // Area (ha) of GM maize (Acr)
CZ DE ES FR NL PT EU
Var Acr Var Acr Var Acr Var Acr Var Acr Var Acr Var Acr
1997* Bt176 0 0 0 0 0 0 0 0 0 0 0 0 0 0
MON810 0 0 0 0 0 0 0 0 0 0 0 0 0 0
Total 0 0 0 0 0 0 0 0 0 0 0 0 0 0
1998** Bt176 0 0 0 0 +2 22 320 +9 1500 0 0 0 0 0 23 820
MON810 0 0 0 0 0 0 +6 0 0 0 0 0 0 0
Total 0 0 0 0 2 22 320 15 1500 0 0 0 0 0 23 820
1999 Bt176 0 0 0 0 0 24 950 0 0 0 0 +1 280 0 25 230
MON810 0 0 0 0 0 0 0 150 0 0 +1 1120 0 1270
Total 0 0 0 0 2 24 950 15 150 +1*** 0 2 1400 0 26 500
2000 Bt176 0 0 0 ? 0 25 280 0 0 0 0 –1 0 0 25 820
MON810 0 0 0 ? 0 0 0 34 0 0 –1 0 0 34
Total 0 0 0 <100 2 25 820 15 34 1 0 0 0 0 25 954
2001 Bt176 0 0 0 ? 0 11 450 0 0 0 0 0 0 0 11 450
MON810 0 0 0 ? 0 0 0 15 0 0 0 0 0 15
Total 0 0 0 <100 2 11 450 15 15 1 0 0 0 0 11 565
2002 Bt176 0 0 0 ? 0 23 280 0 0 0 0 0 0 0 23 280
MON810 0 0 0 ? 0 0 0 10 0 0 0 0 0 10
Total 0 0 0 <100 2 23 280 15 10 1 0 0 0 0 23 390
2003 Bt176 0 0 0 ? +1 26 090 0 0 0 0 0 0 0 26 090
MON810 0 0 0 ? +4 6070 0 17 0 0 0 0 0 6087
Total 0 0 0 <100 7 32 160 15 17 1 0 0 0 0 32 277
2004 Bt176 0 0 0 ? +2, −1 21 810 0 0 0 0 0 0 0 21 810
MON810 0 0 0 ? +7 36 410 0 15 0 0 0 0 +17 36 425
Total 0 0 0 <100 15 58 220 15 15 1 0 0 0 17 58 335
2005 Bt176 0 0 0 0 –4 0 0 0 0 0 0 0 0 0
MON810 0 270 +3 340 +14 53 225 0 493 0 0 0 760 +14 55 088
Total 0 270 3 340 25 53 225 15 493 1 0 0 760 31 55 088
2006 Bt176 0 0 0 0 0 0 0 0 0 0 0 0 0 0
MON810 0 1290 +2 954 +11 53 667 0 5028 0 <10 0 1254 0 62 203
Total 0 1290 5 954 36 53 667 15 5028 1 <10 0 1254 31 62 203
Abbreviations: CZ = the Czech Republic; DE = Germany; ES = Spain; FR = France; NL = the Netherlands; PT = Portugal.
* 23/01/1997: EU approval for the event Bt176 pursuant to Directive 90/220/EEC (Commission Decision 97/98/EC).
** 22/04/1998: EU approval for the events MON810 and T25 pursuant to Directive 90/220/EEC (Commission Decisions 98/294/EC
and 98/293/EC, respectively).
*** Registration of Chardon LL derived from the transgenic event T25.
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and socio-economic issues in the risk analysis of GM
agro-food products. The ‘Norwegian Gene Technology
Acts’ (Myhr and Traavik, 2003) and ‘Swedish Environ-
mental Code’ (Karlsson, 2003a), for instance, require that
(1) “the use of GM crops takes place in an ethical and so-
cially justifiable way, in accordance with the principle of
sustainable development”; and that (2) “the release repre-
sents a benefit to the community”. In the Netherlands, an
‘integrated framework for the assessment of social and
ethical issues in modern biotechnology’ was elaborated
(COGEM, 2003). The Belgian ad hoc committee ‘Sus-
tainability and ethical aspects’ was established in 2003 to
provide a wider assessment of the experimental release
demand of a transgenic apple tree. However, in most of
these cases, MS seemed to experience diﬃculties in se-
curing the conversion of societal concerns into concrete
action.
Restyling II: Regulation 178/2002 concerning the
general principles and requirements of food law,
the establishment of the European Food Safety
Authority (EFSA), and the procedures in matters
of food safety
Adding on to Directive 2001/18, Regulation 178/2002
lays down the general principles of food law and proce-
dures in food and feed safety, as well as the tasks of the
EFSA. With this Regulation, the application of the PP is
further extended to the risk analysis of all food and feed
in the EU, whether or not of GM origin. A uniform ba-
sis for the adoption of the PP is provided by stating that
“in specific circumstances where, following an assess-
ment of available information, the possibility of harmful
eﬀects on health is identified, but scientific uncertainty
persists, provisional risk management measures neces-
sary to ensure the high level of health protection chosen
in the Community may be adopted, pending further sci-
entific information for a more comprehensive risk assess-
ment”. The adopted PP measures shall be “proportionate
and no more restrictive of trade than is required to achieve
the high level of health protection chosen” and “reviewed
within a reasonable period of time”.
In response to a multiple wave of food crises that caused
considerable concerns in European publics about food
safety and the ability of regulatory authorities to fully
protect consumers, the EFSA was created as a European-
wide risk assessment body. By providing ‘independent,
objective and transparent’ science-based advice, the EC
hoped that the EFSA would facilitate EU decisions and
help restoring consumers’ confidence. As such, it has to
reconcile diverse views through its own expert advice.
These complicated objectives have not yet been achieved:
some MS continue to dissent from EFSA opinions, EC
decision proposals gain little support from MS, and the
regulatory-expert conflicts continue to undermine pub-
lic credibility in EU science-based policy (Levidow and
Carr, in press).
Restyling III: Regulation 1829/2003 on genetically
modified food and feed
Since 18 April 2004, Regulation 1829/2003 covers the
commercialization and safety assessment of GM food
and feedstuﬀs, e.g. food/feed containing or consisting of
GMOs, food/feed produced from GMOs, and food con-
taining ingredients produced from GMOs. Prior to this
date, consents for human food use were required under
the Novel Food Regulation, whereas feed uses were as-
sessed under Directive 2001/18 and its predecessor. Prod-
ucts that have been lawfully placed on the European mar-
ket continue, in accordance to Regulation 641/2004, to be
allowed on the market as long as they were notified to the
EC before 18 October 2004. The authorized agro-food
products enter in a Community Register of GM food and
feed, which is made available to the public. The changes
introduced by this GM Food and Feed Regulation are dis-
cussed in the following sections.
A centralized ‘one door-one key’ authorization procedure
To improve the safety standards of GM agro-food prod-
ucts, and to facilitate EU decisions, a new authoriza-
tion procedure was put in place. On the one hand, this
procedure is centralized around the EFSA. In addition
to centralizing administrative procedures, the EFSA is
in charge of harmonizing risk assessment criteria across
MS. In this process, a wide range of experts and actors are
consulted (EFSA, 2004b). MS are specifically consulted
on notifications to positively integrate their views in the
EFSA opinions. However, in practice, only ‘reasonable’
demands are accepted, whilst those that fall outside the
scope of the risk discourse are dismissed on the grounds
that they are not scientific. As such, the more precaution-
ary approaches developed by some MS are hardly accom-
modated.
On the other hand, this procedure is based on a ‘one
door-one key’ approach whereby all the commercial uses
can be covered in a same dossier. Compared to the pro-
cedures of Directive 2001/18 and Regulation 258/97, this
provides a much more streamlined and less cumbersome
authorization procedure. Moreover, it avoids the granting
of consent for a single use, while a product is likely to
be used both for food and feed purposes. This was the
case in the StarLink aﬀair. The maize CBH-351 event
(also called StarLink) was only approved for animal feed.
Nonetheless, in September 2000, traces of it were found
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in food products destined for human consumption in the
United States (US) (Demeke et al., 2006).
Safety assessment
In response to the heated debates that challenged the prin-
ciple of substantial equivalence, the principle was de-
moted to a comparative analysis in the GM Food and
Feed Regulation. The safety assessment of GM food and
feed remains based on a comparative analysis in which
the non-GM counterpart serves as baseline. However, it
requires more evidence of safety than before; more scien-
tific uncertainties are addressed, and the principle can no
longer be used to justify the claim that a risk assessment
is unnecessary (Levidow et al., 2007). This trend stems
from the evolving interpretation given to the principle of
substantial equivalence over time. Since the principle was
intensely criticized by various actors, it was no longer in-
terpreted as the end point of risk assessment, but rather as
the starting point. Whether the GM food was subjected
to further safety assessment depended on the identified
diﬀerences between the GM food and its comparator:
(1) if substantial equivalence was established, the need
for further testing was investigated on a case-by-case ba-
sis; (2) if substantial equivalence was established except
for a single or few specific traits of GM crops, further
tests were done focusing on these traits; and (3) if neither
partial nor total substantial equivalence was established,
the wholesomeness of the food product was assessed. In
the same line of arguments, the simplified procedure was
abandoned under the GM Food and Feed Regulation.
The EC’s Joint Research Centre was established as
the new Community Reference Laboratory for the tech-
nical evaluation and validation of sampling, identification
and detection methods for GM agro-food products, which
is crucial information for controlling the correct imple-
mentation of EU labeling requirements.
Labeling
The labeling provisions of all material intentionally con-
sisting of, containing GM crops or products derived from
them are firmly enshrined by the GM Food and Feed
Regulation. This Regulation extended these provisions
to feeds, seeds, bulk products, foods that are delivered
as such to the final consumers or mass caterers, and to
products in which GMO-derived DNA or protein is no
longer detectable. These requirements go further than the
previous ones, because the use of genetic modification
in itself now is suﬃcient to justify labeling. The label
must be shown in a clearly visible, legible and indeli-
ble manner, and contain the reference ‘genetically mod-
ified’, ‘produced from genetically modified’ or ‘contains
genetically modified’. When a GM food or feed is diﬀer-
ent from its conventional counterpart, the label must also
provide information about any characteristic or property
that renders it diﬀerent. When there is no conventional
counterpart, the label must contain appropriate informa-
tion about the nature and the characteristics of the GM
food or feed. Any characteristic or property that gives rise
to ethical or even religious concerns also has to be men-
tioned. Unfortunately, no further clarifications are given
on the meaning of ethical or religious concerns, making
this aspect of the new regulation on labeling extremely
relative.
Although this point was the target of criticism of
NGOs, products being produced with the help of GMOs –
rather than actually made out of them – do not require la-
beling. As such, meat, eggs, milk and dairy products from
animals reared with GM feed fall beyond the remit of la-
beling provisions. In contrast, other actors considered the
need to label products that do not contain DNA or pro-
tein traces as too excessive. Since substances assisting in
food production, carrier substances or culture media for
micro-organisms are not considered foods, their labeling
is not considered necessary (CEC, 2006).
Adventitious GMO presence in non-GM material
Reviewing twenty years of experience with transgene
containment, Marvier and Van Acker (2005) inferred that
the movement of transgenes beyond their intended desti-
nations is a virtual certainty. Traces of unapproved GM
crop events have been observed in commercially certi-
fied seeds, grains and foodstuﬀs (Demeke et al., 2006;
Friesen et al., 2003; Vogel, 2006), as well as in feral
oilseed rape populations located in ports, and along trans-
portation routes (Saji et al., 2005; Yoshimura et al., 2006).
Various sources can be at the origin of adventitious mix-
ing between GM and non-GM material: the use of im-
pure seed, the natural pollen flow between neighboring
fields, the occurrence of volunteer plants originating from
seeds and/or vegetative plant parts from previous crops,
the human activities during sowing, harvesting, handling,
transporting, storing, importing and processing, and to a
lesser extent the presence of certain sexually compatible
wild relatives and feral plants (Devos et al., 2004, 2005).
Because of this, keeping transgenes on a leash is diﬃ-
cult. In order to cope with this problem, tolerance thresh-
olds were established for the unintentional or technically
unavoidable presence of authorized GM material in non-
GM products in the EU.
A tolerance threshold refers to the maximum admix-
ture level for GM content under which the co-mingled
product does not have to be labeled as being consisting
of, containing or produced from a GMO. More specifi-
cally, Regulation 49/2000 set the labeling threshold for
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the adventitious GMO presence in non-GM foodstuﬀs
at 1% of the food ingredient. Regulation 1829/2003 de-
creased the tolerance threshold to 0.9%, and extended it
to feed and products intended for direct processing. There
is zero tolerance for EU unapproved events, unless they
received a favorable scientific risk assessment for mar-
keting and a detection method is publicly available. In
the latter case, a threshold of 0.5% may be applied tran-
sitionally.
For seeds and organic production, a threshold for GM
content is still lacking, as discussions remained at an im-
passe. Possible thresholds that will be proposed for seeds
will be established at levels such that the GM content
of 0.9% can be guaranteed in food, feed or crops. Pro-
posals range between 0.3% for cross-pollinating crops,
and 0.5% for self-pollinating and vegetatively propagated
crops (SCP, 2001). As no thresholds for the adventitious
GMO presence in non-GM seeds have been established
to date, any seed lot containing authorized GM seeds des-
tined for cultivation in the EU has to be labeled as con-
taining GMOs.
Organic growers prefer a zero tolerance: Regula-
tion 1804/1999 states that the use of GMOs and their
derivatives is not compatible with the organic production
method. However, due to the foreseen de minimis thresh-
old for unavoidable contamination, it may be assumed
that a level between the limit of quantification of a DNA
analysis (0.1%) and 0.9% might be defined in due time by
each MS. Moreover, the EC press release of 21 Decem-
ber 2005 emphasizes that an organic product with an ad-
ventitious GMO content below 0.9% can still be labeled
as organic.
It is often argued that there is no scientific justifica-
tion for the established thresholds. Since GM agro-food
products are declared safe before marketing, thresholds
are not related to safety or health issues. However, they
reflect a balance between diﬀerently framed requests and
technical capabilities (the lower the threshold, the larger
the error): notifiers request high thresholds, whilst NGOs
and consumers demand lower ones. Still, the translation
of labeling thresholds in practice entails enormous tech-
nical and scientific challenges (Holst-Jensen et al., 2006;
Miraglia et al., 2004; Weighardt, 2006).
Co-existence between GM and non-GM crops
As we saw, keeping transgenes on a leash is diﬃ-
cult. To manage this problem of adventitious mixing, a
co-existence policy was introduced through an amend-
ment of Regulation 1829/2003 to Directive 2001/18. Co-
existence refers to the ability of farmers to make a prac-
tical choice between conventional, organic and GM crop
production. More specifically, it has been decided that all
cropping systems should be possible, and that the pres-
ence of one system should not exclude other systems in
the neighborhood. The ability to maintain diﬀerent agri-
cultural production systems is also a prerequisite for pro-
viding a high degree of consumer choice, which is achiev-
able by segregation and identity preservation systems,
and through traceability and labeling provisions. Within
this context, labeling thresholds play a crucial role, since
harm resulting from adventitious mixing will only be
actionable if a certain threshold is exceeded. Moreover,
thresholds will define the required level of containment.
Hence, the eﬀorts needed to meet these thresholds will in-
evitably aﬀect farming and the supply chain management
(Devos et al., 2007).
The co-existence between cropping systems is framed
by the EU as a socio-economic problem arising from
the growing of commercially approved GM crops. Since
these crops were judged as safe, biosafety issues fall be-
yond the remit of co-existence. Although the processes
of vertical gene flow are similar, the context diﬀers
(Schiemann, 2003). Various actors heavily criticize this
distinction: they perceive GM crops as a threat to other
crop productions and even to ecologically sensitive re-
gions (Altieri, 2005; Verhoog et al., 2003).
Due to the heterogeneity in farm structures, crop
patterns and legal environments between MS, the EC
followed the principle of subsidiarity for the implementa-
tion of legal co-existence frames. However, with the em-
powerment of local authorities, the governance of GM
crops was extended to additional players, further compli-
cating its organization. To avoid the proliferation of too
diverse co-existence standards over the EU, and to se-
cure its predefined co-existence scope, the EC guidelines
(2003/556) for the development of national strategies and
practices were elaborated. In these guidelines, the ‘new-
comer pays principle’ was accommodated with GM pro-
duction as the ‘newcomer’. Hence, GM growers may be
required to pay suitable restitution when they cause un-
lawful damages through intentional or negligent actions
and/or fail to take adequate preventive measures to main-
tain adventitious mixing below the tolerance thresholds.
Moreover, through the notification procedure of
Directive 98/3, the EC assesses whether the na-
tional/regional legal proposals for co-existence are in
conformity with Community legislations. Preliminary as-
sessments indicate that the co-existence debate broad-
ened the range of relevant policy uncertainties, further
blurring any distinction between economic, agricultural
and environmental harms. As such, some legal propos-
als favor certain cropping systems over others. That the
legal criterion for co-existence was adopted in the envi-
ronmental Directive 2001/18 may have contributed to this
blurring (EC, 2006; Levidow and Boschert, in press).
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Restyling IV: Regulation 1830/2003 concerning the
traceability and labeling of genetically modified
organisms and the traceability of food and feed
products produced from genetically modified
organisms
Regulation 1830/2003 complements, clarifies and makes
operational some of the labeling and traceability objec-
tives of previous legislations. With the labeling provi-
sions of the Novel Food Regulation, the need for trace-
ability ‘from farm to fork’ was indirectly introduced.
According to Huﬀman (2004), “a labeling policy may
not be eﬀective without maintaining diﬀerent agricultural
production systems, and segregating and tracing of GM
products”. It is Directive 2001/18 that introduced the gen-
eral principle of traceability at all stages of the placing on
the market of GM products. The aim is to provide the
ability to retrieve the history and use or location of a GM
product through a registered identification: specific infor-
mation on the GMO will be transmitted and retained (for
a period of five years) throughout the production and sup-
ply chains, which allows tracking GMO products’ move-
ments. This information can be accessed via a specific
code that is attributed to each GMO from the Community
register, which will act as a unique identifier. Under the
auspices of the Organization for Economic Cooperation
and Development a system for unique identifiers for GM
crops was developed and recently enforced by Regulation
65/2004 at European level (Lezaun, 2006).
In addition to the prerequisite for labeling, traceabil-
ity oﬀers the possibility to withdraw products that have
an unexpected adverse eﬀect to human health or the en-
vironment. In this view, traceability may be seen as a
valuable tool for environmental and health protection, as
well as for monitoring. Moreover, the preamble of Regu-
lation 1830/2003 mentions that “traceability should facil-
itate the implementation of risk management measures in
accordance with the PP”. The products concerned by the
labeling requirements are pre-packaged products consist-
ing of or containing GMOs, and non-pre-packaged prod-
ucts sold to the final consumers.
WILL GM CROPS SPREAD IN THE EUROPEAN
MARKET AFTER THE MORATORIUM?
The regulatory changes discussed above contributed to
the abandon of the de facto EU moratorium in 2004. As a
result, new EC market consents were granted for several
pending notifications, albeit not without discord. More-
over, the freshly granted market consents only covered
food, feed, import and industrial processing, meaning that
most of the approved transgenic crops are still cultivated
outside the EU, subsequently imported and eventually
further processed in the EU. With the submission of no-
tifications covering the marketing of GM stacked events,
today this trend continues (De Schrijver et al., 2007). For
example, a first GM stacked event, MON810 ×MON863
maize has been approved under Directive 2001/18 for im-
port and industrial processing on 13 January 2006. Prod-
ucts derived from an increasing diversity of GM events
thus may be expected in the European supply chains and
retail shelves. Still, a recent qualitative survey of GM
food labels in French supermarkets revealed that there are
almost no GM-labeled products on supermarkets’ shelves
(Gruère, 2006), suggesting that food processors are still
avoiding these products in favor of non-GM alternatives,
or that they only use products in which the GMO content
is kept under the labeling threshold. The few GM food-
stuﬀs that do reach the retail shelves are also likely to
be targeted by pressure groups opposed to genetic mod-
ification (Carter and Gruère, 2003). Retailers avoid GM
products, and ever since 1999, a non-GM European food
market has been induced by public protest combined with
legal labeling and traceability provisions. There is little
doubt that GM crops have been imported mainly as feed
and/or have been processed in feed mixtures for cattle and
poultry (CEC, 2006; Gryson et al., 2007). Indeed, as we
saw, products obtained from animals fed with GM crops
do not require labeling, and as such, escape the debate.
The cultivation of new GM crop events also remains
far on the horizon in the EU. On 7 December 2005, the
EFSA adopted a first positive opinion for cultivation of
the GM potato event EH92-527-1. However, its cultiva-
tion will be restricted to a closed loop system of con-
tractors (EFSA, 2006b). Moreover, the European adop-
tion rate of previously approved GM crops for cultivation
was slow (Demont and Tollens, 2004). With the registra-
tion of seventeen MON810 hybrids in the common seed
catalogue on 8 September 2004, the GM maize cultiva-
tion area increased in France, Germany and Spain, and
expanded to the Czech Republic and Portugal in 2005.
Nonetheless, in 2005, the European cultivation area of
GM maize was approximately 55 000 ha, whilst glob-
ally 21.2 million ha was reached. The registration of
other, more regionally adapted MON810 hybrids in the
German, Spanish and common EU catalogue soon fol-
lowed. These evolutions may increase the adoption of the
transgenic insect resistant hybrids, especially in regions
where the European and/or Mediterranean corn borer are
pests, although this boost may be counterbalanced by le-
gal co-existence constraints and high premium prices of
transgenic seeds (Tab. 3).
CONCLUSION
In general, it has been argued that the de facto morato-
rium on GM crops in the EU gave room to a broader
discussion, adding a societal orientation to the existing
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frame. This discussion has been translated into a thor-
ough renewal of the regulatory frame on GM agro-food
products. The move to cover and embrace societal con-
cerns led to a regulatory regime that imposes the most
stringent criteria for their approval worldwide (cf. WTO
dispute between the US and EU). The debates on and evo-
lutions in the regulatory frame continue to reflect societal
concerns relating to GM agro-food products to various
degrees.
Still, estimating to what extent the regulatory changes
by themselves are helpful in pacifying the underlying
conflict on GM agro-food products in the EU is not easy.
This has much to do with the fact that the public perceive
risks diﬀerently than scientific experts and risk assessors.
Moreover, with the installation of an explicit non-GM
food market in the EU since 1999, it has become diﬃ-
cult to estimate whether members of the public will be-
have as consumers rather than as citizens, and let price,
packaging, availability, the convenience of preparation,
brand names and/or other moral concerns determine their
choices to buy or not GM agro-food products. Generally,
“surveys place respondents in the role of citizens, who
make judgments from society’s point of view, rather than
consumers, who make actual purchase decisions” (Brom,
2000; Noussair et al., 2004). Even then, the acceptability
of buying those products continues to show a large degree
of heterogeneity within EU countries (Lusk et al., 2006;
Spence and Townsend, 2006).
It has been shown how, in response to the societal con-
cerns about harmfulness and scientific uncertainties of
GM agro-food products, various scientific and technical
reforms were made at the level of the risk analysis. In this
context, first, the environmental risk analysis was diﬀer-
entiated from product-specific risk analyses. Second, the
PP was explicitly adopted in 2002 to cope with scien-
tific uncertainties. Consequently, the scope of the ERA
was broadened to include more agro-ecological expertise,
attempts were made to render value judgments and the
limitations of risk assessment more explicit, the environ-
mental PMM and traceability became mandatory, the use
of certain ARM genes was phased out, and the duty of
re-examination of risk analysis was strengthened by lim-
iting the duration of market consent to ten years. Third,
risk assessment methodologies and approaches were har-
monized, and new institutes such as the EFSA were cre-
ated to provide independent, objective and transparent
science-based advice. A centralized one door-one key
approach authorization procedure was implemented to
avoid the adventitious presence of non-authorized GM
material in other produces. Fourth, openings were cre-
ated for public participation and ethical consultation in
the authorization procedure.
Labeling, traceability and public information/regis-
ters formed a legal answer to the general desire of the
public for more information about GM agro-food prod-
ucts, and the specific demand to respect the consumers’
freedom of choice. Labeling indeed allows consumers
to make an informed choice about buying GM agro-
food products. However, labeling may be inappropriate in
some cases, because those who consume the food do not
necessarily buy it. In the EU, there has been an evolution
towards more stringent labeling of all materials ‘inten-
tionally consisting of, containing GM crops or products
derived from them’. Nowadays, the sole use of genetic
modification is suﬃcient to justify labeling, meaning that
even products in which no GMO traces are detectable,
have to be labeled. In addition to guaranteeing a high
degree of consumers’ choice, the freedom of choice of
farmers to cultivate or not GM crops, as well as the main-
tenance of agricultural diversity are ensured through co-
existence.
Despite the apparent progress towards a more sensi-
tive evaluation of GM agro-food products, the societal
disjuncture continues. First, safety issues still occupy a
prominent position in the risk analysis of GM crops, and
restrictions to market consents are only applied when
harm to human health and the environment is at stake.
The legal reforms solidified the science-based policy by
further reducing societal concerns to biosafety risks. That
several concerns about safety have been taken seriously
may reassure some members of the public. However, it
is not clear whether increased safety assurances based
on risk assessments alone make some members of the
public feel any safer. As we saw, lay people widely ex-
pand the concept of risk. Based on the results of the lat-
est Eurobarometer survey, Gaskell et al. (2006) observed
that “the new regulatory frame appears to have done little
to allay the European public’s anxieties about agro-food
biotechnology”, suggesting that “the years of controversy
have led many people in Europe to believe that anything
to do with GM food is undesirable”. Other research on
public attitudes towards GM agro-food products gives in-
dications in this direction. It is suggested that, next to
risk perception, perception of potential benefits is also
determinant for acceptance. Potential risks are weighed
against potential benefits. For a large group, risks even
hardly appear to play a role. In this case, benefits or the
absence thereof seem to be the decisive factor (Gaskell
et al., 2004). The bottleneck is that the European regu-
latory frame on GM crops does not oﬀer the possibility
to consider potential benefits in the actual risk analysis.
There is no legal room to evaluate whether GM crops ful-
fill wider socio-economic and environmental aspirations.
It is not possible to evolve towards a sustainability as-
sessment. Moreover, as the use of the PP is kept within a
narrow scientific context, its linkage to the ideal of sus-
tainable development is hampered.
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Second, the implementation of labeling, in fact leaves
societal and political choices regarding the consumption
of GM agro-food products to the individual. Intrinsic
moral concerns regarding genetic modification remain
unaddressed in the authorization procedure. Opponents
to genetic modification can only avoid GM-labeled prod-
ucts that are on the market: ‘to buy or not to buy’ is their
sole political power.
Third, some openings have been created, oﬀering the
possibility to assess concerns that are explicitly labeled
as ethical. However, these openings seem to be merely
symbolic, since the ethical assessment is not supposed
to change the consent procedure or content, and remains
diﬃcult to implement. This is in analogy with the pub-
lic consultations where only scientific and technical com-
ments are considered, and where larger societal concerns
are a priori excluded. Practical problems in making this
opening workable (towards direct public engagement and
towards the inclusion of societal concerns in authoriza-
tion procedures) can be invoked. However, it may also
reflect the diﬃculty to make narrow and stringent legal
frames coincide fully with complex, broad and often fluc-
tuating ethical concerns. That many societal concerns are
not related to GM crops alone, but questions the whole
agricultural system – of which GM crops only represent
the tip of the iceberg – is illustrative of this.
Fourth, the societal disjuncture regarding GM agro-
food products did not dissipate with the various institu-
tional reforms that led to the upheaval of the de facto
moratorium in 2004. To the contrary, “the prevalent
harmonization strategy aggravated EU-national dishar-
monies rather than reduced them” (Levidow and Carr, in
press). Following investigations of safeguard clause de-
mands made by MS, the EFSA generally concluded that
there is no new information invalidating the contested risk
assessment or justifying a prohibition, since geographi-
cal, ecological or nutritional particularities are generally
ascertained in risk assessments (EFSA, 2006c). More-
over, recent market consents were not granted without
discord. MS still raise various safety objections, continu-
ing to adopt more stringent criteria than EU institutions.
Consequently, a qualified majority is rarely reached at the
Council of Ministers. However, despite the many national
objections and limited support from MS, the EC gener-
ally adopts decisions based on the favorable risk assess-
ment of the EFSA at the end of the authorization pro-
cedure. Although the EC seldom disregards the EFSA
opinions, Stavros Dimas – who represents the Environ-
ment Directorate General of the EC – requested a more
thorough assessment of potential long-term eﬀects of GM
crops at the Vienna conference on the co-existence of ge-
netically modified, conventional and organic crops held
in April 2006. Moreover, under the pressure of the grow-
ing dissatisfaction of some MS, the EC recently asked the
EFSA to provide greater transparency about value judg-
ments and scientific uncertainties in risk assessments, and
to develop a greater consensus between all interested ac-
tors (CEC, 2006; Levidow, 2006). In addition to increas-
ing the transparency in and scientific consistency of risk
assessments, the EFSA recently committed itself to rein-
force the collaboration with MS (EFSA, 2006d).
Fifth, the conflict itself is dynamic, and currently
seems to shift to new topics and domains. With the
currently implemented or proposed co-existence frames
in some MS, the heated debates related to the labeling
thresholds for seeds and organic produce, and the vigor-
ous movement in quest of creating GM-crop-free zones
all over the EU, co-existence seems to be used as a pre-
text for placing new barriers on the path of GM crops.
Moreover, transferring authority to local actors compli-
cated further the governance of GM crops, blurring any
distinction between environmental, economic and agri-
cultural uncertainties.
The GM crop controversy will inevitably be stirred
up by new triggers if, for example, traces of authorized
GM crop events in organic products or of unapproved
GM crop events in conventional products (cf. Bt10 maize,
LL601 rice) are found anew. Much depends on how such
triggers will be interpreted in the contemporary legal and
societal climate (Nisbet and Huge, 2006).
In sum, the EU regulatory frame on GM agro-food prod-
ucts currently aims at a pragmatic balance between vari-
ous legal objectives. In this, only a fraction of the societal
concerns are embraced. Safety issues and the creation of
an internal market stand in the focus of the EU legislation,
whilst the remaining concerns are diverted to the private
sphere through labeling. Today, the explicit role of public
participation and/or of ethical consultation during autho-
rization procedures is at best symbolic. Hence, there is
barely a move to evolve from “reliable expertise” towards
“socially robust expertise” (Nowotny, 2003). However,
the recent policy shift towards greater transparency about
value judgments, diverse viewpoints and scientific uncer-
tainties in risk assessments may be one step forward in
establishing more modest and pluralistic expertise. Still,
it remains to be seen how this policy shift will be trans-
lated in practice at the EU level, and if it will help reach-
ing greater consensus among all interested actors.
Currently, there is no room to implement an inte-
gral sustainability evaluation during market procedures.
This makes it impossible to trade possible risks against
benefits, to compare technological alternatives, to test
the usefulness, and to assess the whole agricultural sys-
tem, thereby integrating larger societal concerns. Such
an approach may promote a better balance between
agricultural production and biodiversity, and may more
explicitly encompass the broader-than-scientific dimen-
sion of actual risk analysis. Out of these discussions will
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follow whether the implementation of an integral sustain-
ability evaluation is desirable, feasible and operational,
and whether it should be limited to GM crops alone.
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